已梭603229 603229 has been collected

31 בדצמ׳ 2024

上周提前布局8.6%仓位，今天加仓10%，跌破成本出局（个人操作，不作为投资参考）
行业：医药生物>化学制药>原料药
概念：生物医药、肝炎概念、新冠特效药

创新药+CRO+外销
公司主要从事特色原料药及医药中间体的研产销，供货真实生物、开拓药业
公司主要从事特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务，主要产品是特色原料药及医药中间体，成熟产品已有双环醇、恩替卡韦、西他沙星、泊沙康唑、非布司他、奈必洛尔、米格列醇等。

Last week, I arranged 8.6% of my position in advance. Today, I increased my position and exited the market when the price fell below the cost (personal operation, not for investment reference)
Industry: Pharmaceutical Biology>Chemical Pharmaceuticals>API
Concepts: Biopharmaceuticals, Hepatitis Concepts, COVID-19 Specific Drugs

Innovative Drugs + CRO + Exports
The company is mainly engaged in the research, production and sales of specialty APIs and pharmaceutical intermediates, supplying Real Biology and Kaituo Pharmaceuticals
The company is mainly engaged in the research, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research and development services for customers. The main products are specialty APIs and pharmaceutical intermediates. Mature products include bicyclol, entecavir, sitafloxacin, posaconazole, febuxostat, nebivolol, miglitol, etc.